European Psychiatry - Volume 33 - March 2016

373 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S369
Introduction Aripiprazole is the firstborn of the new dynasty
of antipsychotic called third generation or neuromodulator of
dopamine-serotonin system. It has proven to be an effective and
well-tolerated antipsychotic. Dual Pathology represents the pres-
ence of comorbidity between mental illness and substance use
disorders. It is an under-diagnosed problem and it is increasing
frequency.
Objectives The aim of this study was to determine and describe
the clinical profile of the patients admitted to the Dual Pathology
Unit (UPD) at TheMontalvos Hospital (Part of Salamanca University
Teaching Hospital, Spain) treated with oral Aripiprazole.
Methods Descriptive, observational, retrospective study of a
sample of patients admitted to the UPD to which oral aripiprazole
was prescribed during hospitalization. A number of sociodemo-
graphic, clinical, and treatment-related variables are described.
Results From a sample of 25 patients and according to DSM-5
criteria (APA, 2013) main diagnoses were: 14 cases of substance-
induced psychotic disorder, 3 cases of schizophrenia; 3 cases of
schizoaffective disorder; 2 cases of bipolar disorder; 1 case of
schizophreniform disorder; 1 case of borderline personality disor-
der; 1 case of personality syndrome. Themost used drugs before the
admittance were cocaine, cannabis and opioids. The average dose
of aripiprazole was 9mg and no side effects or drug interactions
were reported.
Conclusions Apart from its well known efficacy in treament
of psychosis, oral aripiprazole may be a first line treatment for
Dual diagnosis patients, specially those with problems of non-
compliance, due to high level prolactine side effects.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV61
Personality disorders: Which
personality features lead to a
comorbid substance use disorder?
A. Lombardi ∗ ossi , C. Gramaglia , L. Girardi , P. Zeppegno
Università del Piemonte Orientale, Traslational Medicine, Novara,
Italy
∗ Corresponding author.
Introduction Dual Diagnosis (DD) refers to coexistence of a psy-
chiatric disorder, which is often a Personality Disorder (PD), and
a Substance Use Disorder (SUD). Despite DD is a topic of interest
in recent years, few studies have focused on the temperament and
character traits of PD patients with or without a comorbid SUD.
Anyhow, the assessment of personality traits may be helpful to
understand the relation among psychiatric disorder, drug use and
environment in patients with addictive behaviors.
Aims The aim of this study is to compare two subgroups of PD
patients, with and without a comorbid SUD. Sociodemographic,
clinical and personality profile, as assessed with the Temperament
and Character Inventory, will be compared.
Methods We are recruiting patients with a PD diagnosis refer-
ring either the psychiatry ward or outpatient service of the AOU
“Maggiore della Carità”, Novara, Italy; secondly, wewill group them
according to the presence/absence of SUD. Cloninger’s TCI-R will
be administered together with a structured interview to gather
sociodemographic and clinical information.
Results Data collection is ongoing; we expect to find a different
personality profile in PD and DD Patients.
Conclusions Temperament, which is the biological part of the per-
sonality, seems to have an important role in addictive behavior;
therefore assessing the personality traits of DD patients can help
to improve the differential diagnosis and to establish strategies
for treatment and prevention. In particular, sensation seeking and
impulsivity are temperamental characteristics that may favor SUD
in patients with psychiatric disorders.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV62
Video game addiction: Providing
evidence for Internet gaming disorder
through a systematic review of
clinical studies
O. Lopez-Fernandez ∗, D. Kuss , H. Pontes , M. Griffiths
1 IPSY, PSP, Louvain-la-neuve, Belgium
2 IGRU, Division of Psychology, Nottingham, United Kingdom
∗ Corresponding author.
Introduction The American Psychiatric Association introduced in
Internet Gaming Disorder (IGD) in the appendix as a tentative dis-
order in the last edition of the Diagnostic and Statistical Manual of
Mental Disorders. However, currently no systematic review exists
about excessive gaming viewed from a clinical perspective.
Objectives and aims To review clinical studies on gaming addic-
tion in order to ascertain characteristics of both clinical and
research studies to provide retrospective evidence in relation with
the proposed IGD classification (including criteria, measures and
therapies).
Methods A systematic literature reviewof studies published from
1980 to 2015 has been conducted using three major psychology
databases: Academic Search Complete, PsycInfo, and PsycArticles.
A total of 5033 results from peer-reviewed journals were obtained,
where 32 were identified as empirical clinical papers focused on
gaming addiction.
Results The clinical research studies on gaming identified were
published between 1998 and 2015, most of which included
patient samples. Categorizations identified in the research papers
included: (i) patients’ characteristics (e.g., socio-demographics), (ii)
criteria and measures used (e.g., scales to diagnose), (iii) types of
gaming problems (e.g., game genre), (iv) and treatments (e.g., type
of therapy).
Conclusions Findings will be discussed against the background
of the controversial IGD diagnostic criteria proposed in the DSM-5
in order to assess the extent to which previously published clini-
cal knowledge matched the current proposal for including gaming
addiction as behavioral addiction in the next diagnostic manual.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV63
Cannabinoid hyperemesis syndrome
S. López-Romeo∗, G. Ledesma-Iparraguirre
Parc Sanitari Sant Joan de Déu, Psychiatry, Barcelona, Spain
∗ Corresponding author.
Case report A 25-year-old man was attended in multiple times at
Emergency Department by referring abdominal pain and vomiting.
No organic disease was found and he was referred to Psychiatric
Emergency to assess him. He had history of cannabis use (4–5
times/day) during last 5 years. He referred recurrent episodes of
abdominal pain and vomiting since 4 years ago, he had found
that having hot showers alleviate his symptoms. Urine screening
was positive for THC and negative for other drugs. In results of
blood tests, abdominal X-ray, abdominal ultrasonography, abdom-
inal tomography and fibrogastroscopy didn’t find any abnormality.
Hewas diagnosed fromsuffering a somatoformdisorder. Treatment
with Setraline 50mg/day was prescribed and cannabis abstinence
was recommended. He was referred to Mental Health outpatient
service. He maintained cannabis abstinence for 1 month and some
symptoms disappeared. However, 2 months later, he relapsed in